Telbivudine vs tenofovir in hepatitis B e antigen-negative chronic hepatitis B patients: OPTIMA roadmap study

Figure 1 Study design. HBV: Hepatitis B virus.

Figure 2 Proportions of patients achieving hepatitis B virus DNA < 300 (A) or < 169 copies/mL (B), by visit and by baseline hepatitis B virus DNA levels (< 7 or ≥ 7 log₁₀ copies/mL), roadmap intent-to-treat population. HBV: Hepatitis B virus.

Figure 3 Intensification with tenofovir (A) or telbivudine (B), virologic response and aminotransferase normalisation at week 104, roadmap intent-to-treat population. ALT: Alanine aminotransferase; HBV: Hepatitis B virus.

Figure 4 Proportions of patients achieving aminotransferase normalisation, by visit and by baseline hepatitis B virus DNA levels (< 7 or ≥ 7 log₁₀ copies/mL), roadmap intent-to-treat population. ALT: Alanine aminotransferase; HBV: Hepatitis B virus.

Figure 5 Changes in estimated glomerular filtration rate over time with telbivudine and tenofovir, safety population. eGFR: Estimated glomerular filtration rate; MDRD: Modification of diet in renal disease.